MabVax Therapeutics Holdings, Inc. announced the appointment of Jeffrey Eisenberg to the board of directors. Jeffrey Eisenberg served in a variety of senior management positions, including most recently as President, Chief Executive Officer and a board member of Noven Pharmaceuticals, Inc.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
- USD | -.--% | +10.05% | +182.21% |
2020 | MabVax Therapeutics Holdings, Inc. Went Out of Business | CI |
2020 | Second Amended Liquidation Plan & Disclosure Statment Approved for MabVax Therapeutics Holdings, Inc. | CI |
1st Jan change | Capi. | |
---|---|---|
+182.21% | 213K | |
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- MBVXQ Stock
- News MabVax Therapeutics Holdings, Inc.
- MabVax Therapeutics Holdings, Inc. Appoints Jeffrey Eisenberg as Director